Brentuximab Vedotin for Systemic Sclerosis
Public ClinicalTrials.gov record NCT03222492. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Evaluation of Brentuximab Vedotin for Diffuse Cutaneous Systemic Sclerosis BRAVOS: A Phase 1/2 Multicenter Randomized, Double Blinded, Safety Study (ITN075AI)
Study identification
- NCT ID
- NCT03222492
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Enrollment
- 17 participants
Conditions and interventions
Conditions
Interventions
- Brentuximab Vedotin Biological
- Placebo Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 19, 2017
- Primary completion
- Apr 9, 2023
- Completion
- Apr 9, 2023
- Last update posted
- May 4, 2026
2017 – 2023
United States locations
- U.S. sites
- 8
- U.S. states
- 8
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UCLA Medical Center: Division of Rheumatology | Los Angeles | California | 90095 | — |
| Georgetown University Medical Center: Division of Rheumatology | Washington D.C. | District of Columbia | 20057 | — |
| University of Michigan Health System: Department of Internal Medicine, Division of Rheumatology | Ann Arbor | Michigan | 48109 | — |
| Hospital for Special Surgery, New York: Division of Rheumatology | New York | New York | 10021 | — |
| Duke University Medical Center: Division of Rheumatology and Immunology | Durham | North Carolina | 27710 | — |
| University of Pittsburgh Medical Center: Division of Rheumatology and Clinical | Pittsburgh | Pennsylvania | 15217 | — |
| Medical University of South Carolina: Division of Rheumatology & Immunology | Charleston | South Carolina | 29425 | — |
| University of Texas Houston Medical School: Division of Rheumatology and Clinical Immunogenetics | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03222492, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 4, 2026 · Synced May 16, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03222492 live on ClinicalTrials.gov.